We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

QuidelOrtho

Develops, manufactures and markets rapid diagnostic tests that focus on infectious diseases, reproductive health, and... read more Featured Products: More products

Download Mobile App




Novel Adipokine Biomarker Reported for Insulin Resistance and Atherosclerosis

By LabMedica International staff writers
Posted on 21 Jul 2021
Diabetes Mellitus is a chronic condition occurring due to inadequate production or inadequate action of insulin, ultimately leading to hyperglycemia. More...
Prediabetes, regarded as a precursor of diabetes, is a condition with elevated plasma glucose above normal levels, but below that of clinical disease.

Atherosclerotic cardiovascular diseases contribute to the world’s largest disease burden and are a leading cause of morbidity and mortality in both diabetics and prediabetics, accounting for about two third of mortality in diabetics. Increased levels of adipose derived cytokine (adipokine) apart from having immunological role, also have role in insulin resistant states and the process of atherosclerosis.

Medical Scientists at the Dr. Ram Manohar Lohia Hospital (New Delhi, India) included in a case control study 60 prediabetic patients and 60 age, sex, BMI matched controls. In both cases and controls serum levels of fasting and postprandial blood glucose, glycated hemoglobin (HbA1c) using a Vitros dry chemistry analyzer (Ortho Clinical Diagnostics, Bridgend, UK) and fasting insulin levels were measured by Chemiluminescence Immuno Assay (CLIA) on Vitros ECiQ. Homeostatic model assessment of insulin resistance (HOMA-IR) values in both the groups was calculated using fasting glucose and insulin levels. Serum Retinol Binding Protein-4 (RBP4) levels were measured using ELISA (IMMUNDIAGNOSTIK AG, Bensheim, Germany). The values obtained were compared between cases and controls. Carotid Intima-Media Thickness (CIMT) was only measured in cases using B-mode ultrasonography.

The investigators reported that the Median (IQR) of fasting plasma insulin levels (uIU/ml) in cases was 11.3 versus that of controls which was 5.73. HOMA-IR median (IQR) in cases and controls was 3.12 and 1.21 respectively. Median (IQR) for RBP4 in cases was 67.4 which were significantly higher as compared to controls 33.92. Significant positive correlation was seen between RBP4 with both, HOMA-IR and mean CIMT with correlation coefficients of 0.3693 and 0.621 respectively. On performing univariate linear regression analysis it was found that with increase in serum RBP4 levels by 1 mg/L, HOMA-IR and mean CIMT significantly increased by 0.007 units and 0.001 mm respectively.

The authors concluded prediabetics have been found to have more risk of cardiovascular events as compared to normoglycemics. Early assessment of the same with the use of novel biomarkers like RBP4 can be considered for early detection of atherosclerosis in prediabetic individuals. The study was published in the July 2021 issue of the Journal of the Association of Physicians of India.

Related Links:
Dr. Ram Manohar Lohia Hospital
Ortho Clinical Diagnostics
IMMUNDIAGNOSTIK AG



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.